VAXCYTE, INC. Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period
VAXCYTE, INC. (PCVX) reported Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period of 350.75 thousand shares for the 9-month period ending 2024-09-30, per its 10-Q filed 2024-11-05.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod · last filed 2024-11-05
- VAXCYTE, INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, vested in period for the quarter ending 2024-09-30 was 205.23K shares, a 48.09% increase year-over-year.
- VAXCYTE, INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, vested in period for the quarter ending 2024-06-30 was 34.95K shares, a 6.39% increase year-over-year.
- VAXCYTE, INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, vested in period for the quarter ending 2024-03-31 was 110.58K shares, a 144.61% increase year-over-year.
- VAXCYTE, INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, vested in period for the quarter ending 2023-12-31 was 16.25K shares.
- VAXCYTE, INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, vested in period for fiscal 2023 was 232.89K shares, a 193.95% increase from fiscal 2022.
- VAXCYTE, INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, vested in period for fiscal 2022 was 79.23K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period 12 month |
|---|---|---|---|---|
| 2024-09-30 | 205.23K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | 240.18K shares derived: sum of 2 quarters · filed 2024-11-05 | 350.75K shares 10-Q · filed 2024-11-05 | 367.01K shares derived: sum of 4 quarters · filed 2024-11-05 |
| 2024-06-30 | 34.95K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | 145.53K shares 10-Q · filed 2024-08-06 | 161.78K shares derived: sum of 3 quarters · filed 2024-08-06 | 300.36K shares derived: sum of 4 quarters · filed 2024-08-06 |
| 2024-03-31 | 110.58K shares 10-Q · filed 2024-05-08 | 126.83K shares derived: sum of 2 quarters · filed 2024-05-08 | 265.42K shares derived: sum of 3 quarters · filed 2024-05-08 | 298.26K shares derived: sum of 4 quarters · filed 2024-05-08 |
| 2023-12-31 | 16.25K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | 154.84K shares derived: sum of 2 quarters · filed 2024-02-27 | 187.68K shares derived: sum of 3 quarters · filed 2024-02-27 | 232.89K shares 10-K · filed 2024-02-27 |
| 2023-09-30 | 138.58K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | 171.43K shares derived: sum of 2 quarters · filed 2023-11-06 | 216.64K shares 10-Q · filed 2023-11-06 | 216.64K shares derived: sum of 4 quarters · filed 2024-02-27 |
| 2023-06-30 | 32.85K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | 78.06K shares 10-Q · filed 2023-08-08 | 78.06K shares derived: sum of 3 quarters · filed 2024-02-27 | |
| 2023-03-31 | 45.21K shares 10-Q · filed 2023-05-08 | 45.21K shares derived: sum of 2 quarters · filed 2024-02-27 | ||
| 2022-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | 79.23K shares 10-K · filed 2024-02-27 | ||
| 2022-09-30 | 79.23K shares 10-Q · filed 2022-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |